Eslicarbazepine acetate add-on for drug-resistant focal epilepsy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Eslicarbazepine acetate add-on for drug-resistant focal epilepsy

Published:2017-10-25 Issue:1 Volume:2018 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Chang Xian-Chao¹,Yuan Hai²,Wang Yi³,Xu Hui-Qin⁴,Hong Wen-Ke¹,Zheng Rong-Yuan⁴

Affiliation:

1. Ningbo No. 2 Hospital; Department of Neurology; 41 Xibei Street Ningbo Zhejiang China 315010

2. The Second People’s Hospital of Hefei City; Department of Rehabilitation Medicine; No. 246 Heping Road Hefei Anhui China 230011

3. Wenzhou Medical University; Division of Preventive Medicine; University Town Wenzhou Zhejiang China 325000

4. The First Affiliated Hospital of Wenzhou Medical University; Department of Neurology; 2 Fuxue Lane Lucheng District Wenzhou China 325000

Publisher

Wiley

Subject

Pharmacology (medical)

Link

https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008907.pub3/epdf/full

Reference30 articles.

1. Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy;Ben-Menachem;Epilepsy Research,2010

2. Eslicarbazepine acetate: a double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures;Elger;Epilepsia,2007

3. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study;Elger;Epilepsia,2009

4. Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures;Gil-Nagel;Acta Neurologica Scandinavica,2009

5. Sperling MR Abou-Khalil B Harvey J Rogin JB Biraben A Galimberti CA Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: results of a phase III, double-blind, randomized, placebo-controlled trial Epilepsia 2015 244 53

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. NLRP3 Inflammasome Inhibitors for Antiepileptogenic Drug Discovery and Development;International Journal of Molecular Sciences;2024-05-31

2. The efficacy and safety of third-generation antiseizure medications and non-invasive brain stimulation to treat refractory epilepsy: a systematic review and network meta-analysis study;Frontiers in Neurology;2024-01-09

3. Drugs for patients with epilepsy and excessive daytime sleepiness;Epilepsy & Behavior;2021-11

4. Eslicarbazepine acetate add-on therapy for drug-resistant focal epilepsy;Cochrane Database of Systematic Reviews;2021-06-22

5. Pharmacoepidemiology of Antiepileptic Drugs in Children;Journal of Pharmaceutical Negative Results;2021-04-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3